EP3355864A4 - Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci - Google Patents

Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci Download PDF

Info

Publication number
EP3355864A4
EP3355864A4 EP16852272.0A EP16852272A EP3355864A4 EP 3355864 A4 EP3355864 A4 EP 3355864A4 EP 16852272 A EP16852272 A EP 16852272A EP 3355864 A4 EP3355864 A4 EP 3355864A4
Authority
EP
European Patent Office
Prior art keywords
urination
frequency
reducing
composition
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16852272.0A
Other languages
German (de)
English (en)
Other versions
EP3355864A1 (fr
Inventor
David A. Dill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellesley Pharmaceuticals LLC
Original Assignee
Wellesley Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/870,473 external-priority patent/US20160015694A1/en
Application filed by Wellesley Pharmaceuticals LLC filed Critical Wellesley Pharmaceuticals LLC
Publication of EP3355864A1 publication Critical patent/EP3355864A1/fr
Publication of EP3355864A4 publication Critical patent/EP3355864A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16852272.0A 2015-09-30 2016-08-26 Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci Withdrawn EP3355864A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/870,473 US20160015694A1 (en) 2013-03-13 2015-09-30 Composition for reducing the frequency of urination, method of making and use thereof
PCT/US2016/049018 WO2017058428A1 (fr) 2015-09-30 2016-08-26 Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci

Publications (2)

Publication Number Publication Date
EP3355864A1 EP3355864A1 (fr) 2018-08-08
EP3355864A4 true EP3355864A4 (fr) 2019-05-22

Family

ID=58427764

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16852272.0A Withdrawn EP3355864A4 (fr) 2015-09-30 2016-08-26 Composition pour réduire la fréquence de la miction, procédé de fabrication et d'utilisation de celle-ci

Country Status (7)

Country Link
EP (1) EP3355864A4 (fr)
JP (1) JP2018529711A (fr)
KR (1) KR20180066112A (fr)
CN (1) CN108391420A (fr)
AU (1) AU2016331871A1 (fr)
SG (1) SG11201805530RA (fr)
WO (1) WO2017058428A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3389661A4 (fr) * 2015-12-18 2019-12-18 Wellesley Pharmaceuticals, LLC Composition pour réduire la fréquence de la miction, son procédé de fabrication et d'utilisation
CN112569204A (zh) * 2020-12-30 2021-03-30 湖北人福药用辅料股份有限公司 一种普鲁兰多糖、淀粉植物肠溶胶囊及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014018222A1 (fr) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Formulation pharmaceutique pour réduire la fréquence de miction et son procédé d'utilisation
WO2014079922A1 (fr) * 2012-11-21 2014-05-30 Ferring B.V. Composition pour libération immédiate et prolongée
US20140178441A1 (en) * 2010-07-08 2014-06-26 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005732A2 (fr) * 2008-06-16 2010-01-14 Appian Labs, Llc Composition et procédé de préparation de systèmes de libération pour la libération constante (d’ordre zéro) d’agents actifs
NZ718163A (en) * 2012-03-19 2017-09-29 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140178441A1 (en) * 2010-07-08 2014-06-26 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
WO2014018222A1 (fr) * 2012-07-27 2014-01-30 Wellesley Pharmaceuticals, Llc Formulation pharmaceutique pour réduire la fréquence de miction et son procédé d'utilisation
WO2014079922A1 (fr) * 2012-11-21 2014-05-30 Ferring B.V. Composition pour libération immédiate et prolongée

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017058428A1 *

Also Published As

Publication number Publication date
CN108391420A (zh) 2018-08-10
JP2018529711A (ja) 2018-10-11
KR20180066112A (ko) 2018-06-18
SG11201805530RA (en) 2018-07-30
EP3355864A1 (fr) 2018-08-08
AU2016331871A1 (en) 2018-05-17
WO2017058428A1 (fr) 2017-04-06

Similar Documents

Publication Publication Date Title
EP3626803A4 (fr) Composition et procédé de production d'une composition
EP3717484A4 (fr) Procédé pour la fabrication de lumatépérone et de ses sels
EP3142625A4 (fr) Lingette jetable dans les toilettes et son procédé de fabrication
EP3104865A4 (fr) Des procédés pour préparer et utiliser ledit additif sont en outre décrits.
EP3337823A4 (fr) Compositions de support-agent de liaison et leurs procédés de fabrication et d'utilisation
EP3356308A4 (fr) Particules poreuses à base de silicate et de calcium, composition, procédé de fabrication et d'utilisation associé
EP3234060A4 (fr) Composition de fracturation hydraulique, son procédé de production et d'utilisation
EP3594312A4 (fr) Composition, procédé pour sa production et utilisation associée
EP2978409A4 (fr) Composition ophtalmique, son procédé de préparation et son utilisation
EP3166892A4 (fr) Compositions anti-calcaire et procédés de fabrication et d'utilisation associés
EP3373910A4 (fr) Formulation d'échinomycine, procédé de fabrication et méthode d'utilisation de cette dernière
EP3117827A4 (fr) Composition vaginale et son utilisation
EP3516127A4 (fr) Structure et son procédé de fabrication
EP3476872A4 (fr) Matériau d'électrolyte, son procédé de production et son utilisation
EP3535434A4 (fr) Composés de cobalt, procédé de fabrication et procédé d'utilisation associé
EP3681491A4 (fr) Procédés pour la fabrication et l'utilisation d'endoxifène
EP3510134A4 (fr) Composition de nettoyage, son procédé de fabrication et son utilisation
GB2572610B (en) Composition, methods for its production, and its use
EP3551619A4 (fr) Compositions comprenant des promédicaments méthylphénidates, procédés de fabrication et d'utilisation de ces compositions
EP3227298A4 (fr) Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci
EP3530650A4 (fr) Forme cristalline de (r)-4-hydroxy-2-oxo-1-pyrrolidineacétamide, son procédé de préparation et son utilisation
EP3356480A4 (fr) Composition aqueuse à longue durée de conservation et son procédé de fabrication
EP3341006A4 (fr) Compositions et méthodes pour le traitement d'une lésion neurologique
EP3334730A4 (fr) Pyrrolomycines et leurs procédés d'utilisation
EP3685845A4 (fr) Composition et son procédé de production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180424

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190425

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/192 20060101ALI20190417BHEP

Ipc: A61K 9/24 20060101ALI20190417BHEP

Ipc: A61K 9/16 20060101AFI20190417BHEP

Ipc: A61K 9/50 20060101ALI20190417BHEP

Ipc: A61K 31/167 20060101ALI20190417BHEP

Ipc: A61K 9/20 20060101ALI20190417BHEP

Ipc: A61K 9/52 20060101ALI20190417BHEP

Ipc: A61K 31/405 20060101ALI20190417BHEP

Ipc: A61K 45/06 20060101ALI20190417BHEP

Ipc: A61K 31/616 20060101ALI20190417BHEP

Ipc: A61K 31/12 20060101ALI20190417BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191126